Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 14;12(10):e70046.
doi: 10.1002/rcr2.70046. eCollection 2024 Oct.

Ramucirumab-induced ascites with endothelial growth factor receptor mutation-positive non-small cell lung cancer: Two case reports

Keisuke Shiraha  1 , Tomoki Tamura  1 , Taisaku Koyanagi  1 , Takahiro Umeno  1 , Kazuya Nishii  1 , Shoichi Kuyama  1
Affiliations

Ramucirumab-induced ascites with endothelial growth factor receptor mutation-positive non-small cell lung cancer: Two case reports

Keisuke Shiraha et al. Respirol Case Rep. .

Abstract

Ramucirumab (RAM) has been approved for the treatment of non-small cell lung cancer (NSCLC). Here, we report two cases of RAM-induced ascites with epidermal growth factor receptor-mutant NSCLC. Patient 1, a 72-year-old man, developed ascites 20 months after erlotinib (ERL) and RAM administration, which resolved after their discontinuation and performing paracentesis. Patient 2, an 83-year-old woman, developed ascites 9 months after ERL and RAM administration, which resolved after RAM discontinuation and furosemide administration. Ramucirumab administration can cause ascites due to increased hepatic sinusoidal pressure. Clinicians should be aware of RAM-induced ascites in patients with NSCLC and should appropriately manage it.

Keywords: ascites; epidermal growth factor receptor; erlotinib; non‐small cell lung cancer; ramucirumab.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

FIGURE 1
FIGURE 1
Computed tomography conducted in Patient 1 at 20 months after first RAM administration (A), 24 months after first RAM administration (B), 2 months after last RAM administration (C), and 4 months after last RAM administration (D).
FIGURE 2
FIGURE 2
Computed tomography conducted in Patient 2 at 9 months after first RAM administration (A), 13 months after first RAM administration (B), 2 months after last RAM administration (C), and 3 months after last RAM administration (D).
See this image and copyright information in PMC

References

    1. Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, et al. Meta‐analysis of individual patient safety data from six randomized, placebo‐controlled trials with the antiangiogenic VEGFR2‐binding monoclonal antibody ramucirumab. Ann Oncol. 2017;28:2932–2942. - PMC - PubMed
    1. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second‐line treatment in patients with advanced hepatocellular carcinoma following first‐line therapy with sorafenib (REACH): a randomised, double‐blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859–870. - PubMed
    1. Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz‐Ares L, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR‐mutated, advanced non‐small‐cell lung cancer (RELAY): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Oncol. 2019;20:1655–1669. - PubMed
    1. Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Ikenaka Y, et al. The vascular endothelial growth factor receptor KDR/Flk‐1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology. 2001;33:841–847. - PubMed
    1. Arai M, Maruta S, Fan MM, Imai C, Tawada A, Takiguchi Y. Simultaneous chylous ascites and chylothorax during ramucirumab plus docetaxel chemotherapy in a patient with non‐small lung cell cancer. Int Cancer Conf J. 2019;8:114–117. - PMC - PubMed

LinkOut - more resources